Click here to receive MS news via e-mail
Sep 9, 2016
Patients with relapsing-remitting multiple sclerosis (RRMS) receiving siponimod treatment for 24 months had low disease activity and showed no new safety signals, according to an extension of the phase 2 BAF312 on MRI Lesion Given Once Daily (BOLD) study. The extension was conducted by Ludwig Kappos, MD, of the Neurologic Clinic and Proclinic, in the Department of Medicine at the University Hospital Basel in Switzerland, and colleagues, and was published in JAMA Neurology in July, 2016. –
This study extension was dose-blinded and randomized, and the main outcomes included a safety assessment and efficacy measures. The researchers say, “Safety assessment included blood tests, documentation of adverse events at regular scheduled visits and Holter monitoring; key efficacy measures were annualized relapse rate and magnetic resonance imaging lesion activity.”
MS Views and News
Providing educational information, resources and services for those affected by MS